DE69708968T2 - Arylacrylamidderivate als 5HT1 Agoniste oder Antagoniste - Google Patents

Arylacrylamidderivate als 5HT1 Agoniste oder Antagoniste

Info

Publication number
DE69708968T2
DE69708968T2 DE69708968T DE69708968T DE69708968T2 DE 69708968 T2 DE69708968 T2 DE 69708968T2 DE 69708968 T DE69708968 T DE 69708968T DE 69708968 T DE69708968 T DE 69708968T DE 69708968 T2 DE69708968 T2 DE 69708968T2
Authority
DE
Germany
Prior art keywords
agonists
antagonists
arylacrylamide
derivatives
arylacrylamide derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69708968T
Other languages
English (en)
Other versions
DE69708968D1 (de
Inventor
Harry Ralph Howard
Barbara Eileen Segelstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of DE69708968D1 publication Critical patent/DE69708968D1/de
Application granted granted Critical
Publication of DE69708968T2 publication Critical patent/DE69708968T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE69708968T 1996-05-28 1997-05-01 Arylacrylamidderivate als 5HT1 Agoniste oder Antagoniste Expired - Fee Related DE69708968T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1858096P 1996-05-28 1996-05-28

Publications (2)

Publication Number Publication Date
DE69708968D1 DE69708968D1 (de) 2002-01-24
DE69708968T2 true DE69708968T2 (de) 2002-04-25

Family

ID=21788674

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69708968T Expired - Fee Related DE69708968T2 (de) 1996-05-28 1997-05-01 Arylacrylamidderivate als 5HT1 Agoniste oder Antagoniste

Country Status (9)

Country Link
US (1) US6258953B1 (de)
EP (1) EP0810220B1 (de)
JP (1) JP3026948B2 (de)
AT (1) ATE210649T1 (de)
CA (1) CA2206122C (de)
DE (1) DE69708968T2 (de)
DK (1) DK0810220T3 (de)
ES (1) ES2166046T3 (de)
PT (1) PT810220E (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
EP0952154B1 (de) * 1998-04-16 2004-08-18 Pfizer Products Inc. N-Acyl und N-Aroyl Aralkylamide
PE20000942A1 (es) * 1998-07-31 2000-09-28 Lilly Co Eli Derivados de amida, carbamato y urea
US6617351B1 (en) 1998-07-31 2003-09-09 Eli Lilly And Company Amide, carbamate, and urea derivatives
WO2002096858A1 (en) * 2001-05-31 2002-12-05 Bristol-Myers Squibb Company Cinnamide derivatives as kcnq potassium channel modulators
US7351719B2 (en) 2002-10-31 2008-04-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds
WO2004047744A2 (en) 2002-11-22 2004-06-10 Bristol-Myers Squibb Company 3-heterocyclic benzylamide derivatives as potassium channel openers
EP1565190A4 (de) 2002-11-22 2006-04-26 Bristol Myers Squibb Co Arylcyclopropylcarboxylsäureamide als kaliumkanal-öffner
AU2003295782A1 (en) 2002-11-22 2004-06-18 Bristol-Myers Squibb Company Pyridinyl, pyrimidinyl and pyrazinyl amides as potassium channel openers
WO2004047745A2 (en) 2002-11-22 2004-06-10 Bristol-Myers Squibb Company 3-(pyridinyl-piperazin-1-yl)-phenylethyl amides as potassium channel openers
US7045551B2 (en) 2002-11-22 2006-05-16 Bristol-Myers Squibb Company 1-aryl-2-hydroxyethyl amides as potassium channel openers
DE10360745A1 (de) * 2003-12-23 2005-07-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
US7592373B2 (en) 2003-12-23 2009-09-22 Boehringer Ingelheim International Gmbh Amide compounds with MCH antagonistic activity and medicaments comprising these compounds
US20050171095A1 (en) * 2004-01-06 2005-08-04 Pfizer Inc Combination of CRF antagonists and 5-HT1B receptor antagonists
JP2007537151A (ja) * 2004-01-29 2007-12-20 ファイザー・プロダクツ・インク γ−アミノ酪酸モジュレータと５−ＨＴ１Ｂ受容体アンタゴニストとの組合せ
CA2565996A1 (en) * 2004-05-11 2005-11-17 Pfizer Products Inc. Combination of atypical antipsychotics and 5-ht1b receptor antagonists
CN102515996B (zh) * 2011-11-14 2015-11-25 南开大学 一种合成β-芳基丙烯酰胺类化合物的方法
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
US11135207B2 (en) 2016-12-13 2021-10-05 Centaurus Therapeutics Inhibitors of dihydroceramide desaturase for treating disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4564685A (en) * 1983-03-10 1986-01-14 Findlay John W A Diphenylmethane compounds
PT689536E (pt) * 1993-03-16 2001-11-30 Pfizer Derivados de naftaleno

Also Published As

Publication number Publication date
PT810220E (pt) 2002-04-29
DK0810220T3 (da) 2002-03-18
ATE210649T1 (de) 2001-12-15
DE69708968D1 (de) 2002-01-24
CA2206122A1 (en) 1997-11-28
EP0810220A1 (de) 1997-12-03
MX9703899A (es) 1998-06-30
JP3026948B2 (ja) 2000-03-27
EP0810220B1 (de) 2001-12-12
US6258953B1 (en) 2001-07-10
ES2166046T3 (es) 2002-04-01
CA2206122C (en) 2002-03-05
JPH1095765A (ja) 1998-04-14

Similar Documents

Publication Publication Date Title
ATE210649T1 (de) Arylacrylamidderivate als 5ht1 agoniste oder antagoniste
ATE243697T1 (de) Substitutierte heterozyclische derivate als crf antagonisten
ID18883A (id) Pesaing 5-ht 1f
DK0957099T3 (da) Heterocykliske carboxamider
ATE168992T1 (de) 7-substituierte-9-substituierte glycylamido-6- demethyl-6-deoxytetracycline
PT896533E (pt) Pentafluorobenzenosulfonamidas e analogos
FI920023A0 (fi) Heteroarylpiperazinfoereningar som antipsykotiska aemnen.
DK1109817T3 (da) Phosphohalogenhydriner, deres fremstilling og anvendelse
DE60121461D1 (de) Kondensierte pyridoindolderivate
FI900041A (fi) Substituerade indol-, benzofuran- och benzotiopenderivat saosom 5-lipoxigenasinhibitorer,
PT952154E (pt) N-acil- e n-aroil-aralquilamidas
ID23053A (id) Karboksamida yang digunakan sebagai agonis 5-ht <if>
ES2178765T3 (es) Nuevos derivados de 1,7,7-trimetil-biciclo (2.2.1) heptano.
DK0767782T3 (da) Aryl- og heteroarylalkoxynaphthalenderivater
ITMI930819A1 (it) Derivati eterobiciclici ad attivita' fungicida
PT1140932E (pt) Derivados de 1,8-benzonaftiridina

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee